We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Tempus AI (NASDAQ:TEM) reported first-quarter 2026 revenue of $348.1 million, up a little over 36% year over year, as the company posted growth across both its diagnostics and data and applications segments and raised its full-year outlook. Founder and CEO Eric Lefkofsky said diagnostics revenue ca
Moby summary of Tempus AI, Inc.'s Q1 2026 earnings call
Investors are watching Tempus AI (NASDAQ:TEM) ahead of first-quarter results due after the close tomorrow. The stock burst into investor consciousness in January 2025 after Nancy Pelosi disclosed a position, ran past $100, and has since shed nearly half its value. From Pelosi Halo to Show-Me Story Pelosi’s market-beating track record has turned her trades ... Can Nancy Pelosi’s Favorite AI Stock Hope to Regain Its Momentum?
Tempus AI Inc. (NASDAQ:TEM) is one of the best up and coming stocks with highest upside potential. On April 23, Tempus AI and the Keck School of Medicine of USC launched a multi-faceted collaboration aimed at integrating artificial intelligence and data-driven insights into Southern California’s healthcare landscape. This partnership will impact over 1.5 million annual […]
Tempus AI (TEM) has been drawing attention after recent share price moves, with the stock showing a gain over the past month but a decline across the past 3 months and year to date. See our latest analysis for Tempus AI. The recent 10.61% 1 month share price return contrasts with a 16.38% 3 month share price decline and a 19.79% year to date share price loss. Recent momentum therefore appears more like a short term bounce than a sustained trend, even though the 1 year total shareholder return...
Tempus AI (NasdaqGS:TEM) was named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. The company expanded its clinical and research reach through a multi year collaboration with the Keck School of Medicine of USC and Keck Medicine of USC. The partnership is aimed at advancing AI driven precision medicine and applying Tempus tools across patient care and research programs. Tempus AI focuses on applying artificial intelligence to precision medicine, with products that...
TruBridge (TBRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.